Patients received 12 mg/day (for bodyweight ≥ 60 kg) or 8 mg/day (for bodyweight < 60 kg) oral lenvatinib daily. The lenvatinib dose was interrupted and subsequently reduced to 8 mg and 4 mg/day or 4 mg every other day when grade 3 or greater adverse events according to the common terminology criteria for adverse events version 5.0 occurred. When lenvatinib treatment was discontinued due to adverse event or progressive disease, another systemic therapy such as sorafenib, regorafenib, cabozantinib, and ramucirumab, was administered if applicable.
Protocol detail
Dose Adjustment for Lenvatinib Adverse Events
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Corresponding Organization :
Other organizations : Hyogo University, Kyoto University
Top 5 similar protocols
Variable analysis
independent variables
- Lenvatinib dose (12 mg/day for bodyweight ≥ 60 kg, 8 mg/day for bodyweight < 60 kg)
- Lenvatinib dose interruption and reduction (to 8 mg and 4 mg/day or 4 mg every other day) when grade 3 or greater adverse events occurred
- Administration of another systemic therapy (sorafenib, regorafenib, cabozantinib, and ramucirumab) when lenvatinib treatment was discontinued due to adverse event or progressive disease
- Occurrence of grade 3 or greater adverse events
- Not explicitly mentioned
- Not explicitly mentioned
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
Sign up for free or login to display all annotations
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!